Alkermes (ALKS) Non Operating Income (2010 - 2026)
Alkermes' (ALKS) quarterly Non Operating Income came in at -$20.2 million in Q2 2026, down 270.55% year-over-year from $11.9 million in Q2 2025, and down 48.24% quarter-over-quarter from -$13.6 million in Q1 2026.
Analysis
Alkermes (ALKS) Non Operating Income (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has reported Non Operating Income for 17 consecutive years, with -$20.2 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Non Operating Income fell 270.55% year-over-year to -$20.2 million in Q2 2026; TTM through Jun 2026 was -$19.9 million, a 155.03% decrease from a year earlier, with the FY2025 full-year figure at $37.5 million, up 62.21% from the prior year.
- Non Operating Income was -$20.2 million for Q2 2026 at Alkermes, down from -$13.6 million in the prior quarter.
- Over five years, Non Operating Income peaked at $11.9 million in Q2 2025 and troughed at -$20.2 million in Q2 2026.
- A 5-year average of $505055.6 and a median of $2.9 million in 2023 frame the typical range for Non Operating Income.
- Across the five-year window, Non Operating Income tumbled 729.04% in 2022 and surged 1120.71% in 2024, its largest moves.
- Over 5 years, Non Operating Income stood at -$1.1 million in 2022, then soared by 433.18% to $3.7 million in 2023, then surged by 95.41% to $7.2 million in 2024, then sank by 68.43% to $2.3 million in 2025, then plunged by 989.97% to -$20.2 million in 2026.
- The last three Non Operating Income figures came in at -$20.2 million (Q2 2026), -$13.6 million (Q1 2026), and $2.3 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn | - |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn | - |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn | - |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - | -139.24 Mn |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn | 41.90 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn | -20.23 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -20.23 Mn |
| Mar 31, 2026 | -13.65 Mn |
| Dec 31, 2025 | 2.27 Mn |
| Sep 30, 2025 | 11.66 Mn |
| Jun 30, 2025 | 11.86 Mn |
| Mar 31, 2025 | 11.70 Mn |
| Dec 31, 2024 | 7.20 Mn |
| Sep 30, 2024 | 5.47 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 3.60 Mn |
| Dec 31, 2023 | 3.69 Mn |
| Sep 30, 2023 | 3.51 Mn |
| Jun 30, 2023 | 560,000.00 |
| Mar 31, 2023 | -361,000.00 |
| Dec 31, 2022 | -1.11 Mn |
| Sep 30, 2022 | -6.73 Mn |
| Jun 30, 2022 | 1.21 Mn |
| Mar 31, 2022 | -18.41 Mn |
| Dec 31, 2021 | -2.16 Mn |
| Sep 30, 2021 | -6.88 Mn |